<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02720068</url>
  </required_header>
  <id_info>
    <org_study_id>4280-001</org_study_id>
    <secondary_id>2017-001464-38</secondary_id>
    <secondary_id>MK-4280-001</secondary_id>
    <secondary_id>183971</secondary_id>
    <nct_id>NCT02720068</nct_id>
  </id_info>
  <brief_title>Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)</brief_title>
  <official_title>A Phase 1 Trial of MK-4280 as Monotherapy and in Combination With Pembrolizumab With or Without Chemotherapy or Lenvatinib (E7080/MK-7902) in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety and pharmacokinetics study of favezelimab as monotherapy and in combination&#xD;
      with pembrolizumab AND favezelimab/pembrolizumab as monotherapy in adults with metastatic&#xD;
      solid tumors for which there is no available therapy which may convey clinical benefit. Part&#xD;
      A of this study is a dose escalation design in which participants receive favezelimab as&#xD;
      monotherapy or favezelimab in combination with pembrolizumab. Part B is a dose confirmation&#xD;
      design to estimate the recommended Phase 2 dose (RP2D), as determined by dose-limiting&#xD;
      toxicity, for favezelimab in combination with pembrolizumab or pembrolizumab and lenvatinib&#xD;
      in participants with advanced solid tumors. Part B will also assess the efficacy of&#xD;
      favezelimab as monotherapy; favezelimab in combination with pembrolizumab with and without&#xD;
      chemotherapy; favezelimab in combination with pembrolizumab and lenvatinib; and&#xD;
      favezelimab/pembrolizumab as monotherapy in expansion cohorts. Participants who have&#xD;
      completed the initial course of treatment and have investigator-determined progressive&#xD;
      disease may be eligible for a second course of an additional 17 cycles of study treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2, 2016</start_date>
  <completion_date type="Anticipated">December 13, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 13, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)</measure>
    <time_frame>Up to approximately 52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experience at Least One Adverse Event (AE)</measure>
    <time_frame>Up to approximately 7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinue Study Drug Due to an AE</measure>
    <time_frame>Up to approximately 7 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Favezelimab When Administered as Monotherapy</measure>
    <time_frame>At designated time points (Up to approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Favezelimab When Administered in Combination With Pembrolizumab</measure>
    <time_frame>At designated time points (Up to approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Favezelimab When Administered in Combination With Pembrolizumab and mFOLFOX7</measure>
    <time_frame>At designated time points (Up to approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Favezelimab When Administered in Combination With Pembrolizumab and FOLFIRI</measure>
    <time_frame>At designated time points (Up to approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Favezelimab When Administered in Combination With Pembrolizumab and Lenvatinib</measure>
    <time_frame>At designated time points (Up to approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Pembrolizumab When Administered in Combination With Favezelimab and mFOLFOX7</measure>
    <time_frame>At designated time points (Up to approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Pembrolizumab When Administered in Combination With Favezelimab and FOLFIRI</measure>
    <time_frame>At designated time points (Up to approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Pembrolizumab When Administered in Combination With Favezelimab and Lenvatinib</measure>
    <time_frame>At designated time points (Up to approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Lenvatinib When Administered in Combination With Pembrolizumab and Favezelimab</measure>
    <time_frame>At designated time points (Up to approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) as Determined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as Assessed by Investigator Review of Favezelimab Alone and in Combination With Pembrolizumab</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR as Determined by RECIST 1.1 as Assessed by Investigator Review of Two Doses of Favezelimab in Combination With Pembrolizumab for Participants With Advanced Solid Tumors in Cohort E</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR as Determined by RECIST 1.1 as Assessed by Investigator Review of Favezelimab in Combination With Pembrolizumab and mFOLFOX7 for Participants With Advanced Solid Tumors in Cohort B</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR as Determined by RECIST 1.1 as Assessed by Investigator Review of Favezelimab in Combination With Pembrolizumab and FOLFIRI for Participants With Advanced Solid Tumors in Cohort B</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR as Determined by RECIST 1.1 as Assessed by Investigator Review of Favezelimab in Combination With Pembrolizumab and Lenvatinib for Participants With Advanced Solid Tumors in Cohort G</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Favezelimab When Administered as a Co-Formulation With Pembrolizumab (MK-4280A)</measure>
    <time_frame>At designated time points (Up to approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Favezelimab When Administered Sequentially With Pembrolizumab</measure>
    <time_frame>At designated time points (Up to approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Pembrolizumab When Administered as a Co-Formulation With Favezelimab (MK-4280A)</measure>
    <time_frame>At designated time points (Up to approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Pembrolizumab When Administered Sequentially With Favezelimab</measure>
    <time_frame>At designated time points (Up to approximately 2 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Anticipated">576</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Part A: Favezelimab Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive favezelimab Dose A intravenous (IV) infusion on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Favezelimab Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive favezelimab Dose B IV infusion on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Favezelimab Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive favezelimab Dose C IV infusion on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Favezelimab Dose D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive favezelimab Dose D IV infusion on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Favezelimab Dose E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive favezelimab Dose E IV infusion on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Favezelimab Dose A+Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive favezelimab Dose A IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Favezelimab Dose B+Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive favezelimab Dose B IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Favezelimab Dose C+Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive favezelimab Dose C IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Favezelimab Dose D+Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive favezelimab Dose D IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Favezelimab Dose E+Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive favezelimab Dose E IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Favezelimab Monotherapy Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive favezelimab monotherapy dose IV infusion on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Favezelimab Dose F+Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive favezelimab Dose F IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Favezelimab Dose G+Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive favezelimab Dose G IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Favezelimab Dose H+Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive favezelimab Dose H IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Favezelimab Dose G+Pembro+mFOLFOX7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive favezelimab Dose G IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle PLUS mFOLFOX7 (oxaliplatin 85 mg/m^2 IV, leucovorin [calcium folinate] 400 mg/m^2 IV and fluorouracil [5-FU] 2400 mg/m^2 IV over 46 to 48 hours every 2 weeks [Q2W]).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Favezelimab Dose G+Pembro+FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive favezelimab Dose G IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV administered sequentially on Day 1 of each 21-day cycle PLUS FOLFIRI (irinotecan 180 mg/m^2 IV, leucovorin [calcium folinate] 400 mg/m^2 IV and 5-FU 2400 mg/m^2 IV over 46 to 48 hours Q2W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Favezelimab/Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive favezelimab/pembrolizumab (favezelimab and pembrolizumab administered as a co-formulation) IV infusion on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Favezelimab Dose G+Pembro+Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive favezelimab Dose G IV infusion on Day 1 of each 21 day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle PLUS oral lenvatinib (20 mg) each day of 21-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Favezelimab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Part A: Favezelimab Dose A</arm_group_label>
    <arm_group_label>Part A: Favezelimab Dose A+Pembro</arm_group_label>
    <arm_group_label>Part A: Favezelimab Dose B</arm_group_label>
    <arm_group_label>Part A: Favezelimab Dose B+Pembro</arm_group_label>
    <arm_group_label>Part A: Favezelimab Dose C</arm_group_label>
    <arm_group_label>Part A: Favezelimab Dose C+Pembro</arm_group_label>
    <arm_group_label>Part A: Favezelimab Dose D</arm_group_label>
    <arm_group_label>Part A: Favezelimab Dose D+Pembro</arm_group_label>
    <arm_group_label>Part A: Favezelimab Dose E</arm_group_label>
    <arm_group_label>Part A: Favezelimab Dose E+Pembro</arm_group_label>
    <arm_group_label>Part B: Favezelimab Dose F+Pembro</arm_group_label>
    <arm_group_label>Part B: Favezelimab Dose G+Pembro</arm_group_label>
    <arm_group_label>Part B: Favezelimab Dose G+Pembro+FOLFIRI</arm_group_label>
    <arm_group_label>Part B: Favezelimab Dose G+Pembro+Lenvatinib</arm_group_label>
    <arm_group_label>Part B: Favezelimab Dose G+Pembro+mFOLFOX7</arm_group_label>
    <arm_group_label>Part B: Favezelimab Dose H+Pembro</arm_group_label>
    <arm_group_label>Part B: Favezelimab Monotherapy Dose</arm_group_label>
    <other_name>MK-4280</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Part A: Favezelimab Dose A+Pembro</arm_group_label>
    <arm_group_label>Part A: Favezelimab Dose B+Pembro</arm_group_label>
    <arm_group_label>Part A: Favezelimab Dose C+Pembro</arm_group_label>
    <arm_group_label>Part A: Favezelimab Dose D+Pembro</arm_group_label>
    <arm_group_label>Part A: Favezelimab Dose E+Pembro</arm_group_label>
    <arm_group_label>Part B: Favezelimab Dose F+Pembro</arm_group_label>
    <arm_group_label>Part B: Favezelimab Dose G+Pembro</arm_group_label>
    <arm_group_label>Part B: Favezelimab Dose G+Pembro+FOLFIRI</arm_group_label>
    <arm_group_label>Part B: Favezelimab Dose G+Pembro+Lenvatinib</arm_group_label>
    <arm_group_label>Part B: Favezelimab Dose G+Pembro+mFOLFOX7</arm_group_label>
    <arm_group_label>Part B: Favezelimab Dose H+Pembro</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>KEYTRUDA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Part B: Favezelimab Dose G+Pembro+mFOLFOX7</arm_group_label>
    <other_name>ELOXATIN®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Part B: Favezelimab Dose G+Pembro+FOLFIRI</arm_group_label>
    <other_name>CAMPTOSAR®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin (Calcium Folinate)</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Part B: Favezelimab Dose G+Pembro+FOLFIRI</arm_group_label>
    <arm_group_label>Part B: Favezelimab Dose G+Pembro+mFOLFOX7</arm_group_label>
    <other_name>WELLCOVORIN®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil [5-FU]</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Part B: Favezelimab Dose G+Pembro+FOLFIRI</arm_group_label>
    <arm_group_label>Part B: Favezelimab Dose G+Pembro+mFOLFOX7</arm_group_label>
    <other_name>ADRUCIL®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Favezelimab/Pembrolizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Part B: Favezelimab/Pembrolizumab</arm_group_label>
    <other_name>MK-4280A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Oral</description>
    <arm_group_label>Part B: Favezelimab Dose G+Pembro+Lenvatinib</arm_group_label>
    <other_name>E7080</other_name>
    <other_name>MK-7902</other_name>
    <other_name>LENVIMA®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Part A and Part B: Has histologically or cytologically-confirmed metastatic solid&#xD;
             tumor.&#xD;
&#xD;
          -  Has measurable disease by immune-related Response Evaluation Criteria in Solid Tumors&#xD;
             (irRECIST) 1.1 criteria.&#xD;
&#xD;
          -  Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)&#xD;
             Performance Scale.&#xD;
&#xD;
          -  Demonstrates adequate organ function.&#xD;
&#xD;
          -  If female, is not pregnant or breastfeeding, and if of child-bearing potential, is&#xD;
             willing to use an adequate method of contraception for the course of the study and for&#xD;
             at least 180 days after the last dose of chemotherapy, 120 days after the last dose of&#xD;
             pembrolizumab or favezelimab, or 30 days after the last dose of lenvatinib, whichever&#xD;
             occurs last.&#xD;
&#xD;
          -  If male with a female partner(s) of child-bearing potential, both must agree to use an&#xD;
             adequate method of contraception starting with the first dose of study drug through 95&#xD;
             days after the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has had chemotherapy, radiation or biological cancer therapy within 4 weeks prior to&#xD;
             the first dose of study drug, or has not recovered to Common Terminology Criteria for&#xD;
             Adverse Events (CTCAE) Grade 0 or 1 from the AEs due to cancer therapeutics&#xD;
             administered more than 4 weeks earlier (this includes participants with previous&#xD;
             immunomodulatory therapy with residual immune-related [ir]AEs).&#xD;
&#xD;
          -  Is currently participating and receiving study therapy or has participated in a study&#xD;
             of an investigational agent and received study therapy or used an investigational&#xD;
             device within 4 weeks of the first dose of study drug.&#xD;
&#xD;
          -  Has received previous treatment with another agent targeting the lymphocyte-activation&#xD;
             gene 3 (LAG-3) receptor.&#xD;
&#xD;
          -  Has received previous treatment with an immunomodulatory therapy (e.g. anti-programmed&#xD;
             cell death-1/anti-programmed cell death-ligand 1 [anti-PD-1/anti-PD-L1] or cytotoxic&#xD;
             T-lymphocyte-associated protein 4 [CTLA 4] agent) and was discontinued from that&#xD;
             therapy due to a Grade 3 or higher irAE.&#xD;
&#xD;
          -  Is expected to require any other form of antineoplastic therapy while on study.&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             in excess of replacement doses, or on any other form of immunosuppressive medication.&#xD;
&#xD;
          -  Has a history of a previous, additional malignancy, unless potentially curative&#xD;
             treatment has been completed, with no evidence of malignancy for 5 years. Time frame&#xD;
             exceptions include successful definitive resection of basal cell carcinoma of the&#xD;
             skin, superficial bladder cancer or in situ cervical cancer, or other in situ cancers.&#xD;
&#xD;
          -  Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis.&#xD;
&#xD;
          -  Has had a severe hypersensitivity reaction to treatment with another monoclonal&#xD;
             antibody.&#xD;
&#xD;
          -  Has an active autoimmune disease or a documented history of autoimmune disease, except&#xD;
             vitiligo or resolved childhood asthma/atopy.&#xD;
&#xD;
          -  Has an active infection requiring therapy.&#xD;
&#xD;
          -  Has history of (non-infectious) pneumonitis that required steroids or has current&#xD;
             pneumonitis.&#xD;
&#xD;
          -  Has had a prior stem cell or bone marrow transplant.&#xD;
&#xD;
          -  Has a known history of or screens positive for Human Immunodeficiency Virus (HIV),&#xD;
             active chronic or acute Hepatitis B or Hepatitis C.&#xD;
&#xD;
          -  Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the study.&#xD;
&#xD;
          -  Is a regular user as determined by investigator judgment (including &quot;recreational&#xD;
             use&quot;) of any illicit drugs or has a recent history (within the last year) of substance&#xD;
             abuse (including alcohol), at the time of signing informed consent.&#xD;
&#xD;
          -  Has symptomatic ascites or pleural effusion. A participant who is clinically stable&#xD;
             following treatment for these conditions (including therapeutic thoraco- or&#xD;
             paracentesis) is eligible.&#xD;
&#xD;
          -  Has clinically significant heart disease that affects normal activities.&#xD;
&#xD;
          -  Has received a live-virus vaccine within 30 days of planned start of study drug.&#xD;
             Seasonal flu vaccines that do not contain live virus are permitted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0008)</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0019)</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0020)</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0002)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0001)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merck Canada</name>
      <address>
        <city>Kirkland</city>
        <state>Quebec</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical Information Centre Centre d'information medicale Merck Canada Inc.</last_name>
      <phone>514-428-8600 / 1-800-567-2594</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme (China) Ltd.</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zaiqi Wang</last_name>
      <phone>+86 10 5860 9288</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Sharp &amp; Dohme GmbH</name>
      <address>
        <city>Haar</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>German Medical Information Center</last_name>
      <phone>49 800 673 673 673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Co. Ltd.</name>
      <address>
        <city>Hod Hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gally Teper</last_name>
      <phone>972-9-9533310</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD K.K.</name>
      <address>
        <city>Chiyoda-Ku, Tokyo</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Japan Call Center</last_name>
      <phone>81-3-6272-1957</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Korea LTD</name>
      <address>
        <city>Seoul</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jongho Ahn</last_name>
      <phone>82-2-331-2000 2015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Polska Sp. Z o.o.</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Johansson</last_name>
      <phone>48 22ý478 43 24</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp and Dohme de Espana S.A.</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lourdes Lopez-Bravo</last_name>
      <phone>(0034) 913210654</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) - Full Text View - ClinicalTrials.gov</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 22, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2016</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD1</keyword>
  <keyword>PD-1</keyword>
  <keyword>PDL1</keyword>
  <keyword>PD-L1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

